Virginia Commonwealth University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Virginia Commonwealth University sits in the top decile of US sponsors by registered trial count (#63 of 15,742 sponsors by registered trial count).

558 total trials 77 currently recruiting 380 completed early-phase tilt top decile by trial count

Virginia Commonwealth University: 558 sponsored US clinical trials, 77 recruiting.

Virginia Commonwealth University sponsors 558 registered US clinical trials on ClinicalTrials.gov, 77 of them currently recruiting, and 380 completed. 35 of these trials are in Phase 3-4 (later-stage) and 145 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 8 trials.

Top-decile sponsor footprint

Virginia Commonwealth University ranks in the top decile of sponsors by registered trial count (#63 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 45/100

380 of 462 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

558 total, page 2 of 12

RECRUITING Phase 1

Cryospray Therapy for Benign Airway Stenosis

NCT06085209

RECRUITING NA

Health Education Approach to Lung Screening

NCT06070870

RECRUITING

Testing of Online Version of QAPS

NCT05905523

RECRUITING Phase 2

Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder

NCT05886582

RECRUITING

The Impact of Chronic E-Cigarette Usage on Microvascular Health

NCT06860698

RECRUITING

Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis

NCT05720663

RECRUITING NA

Comprehensive Tobacco Cessation for Cancer Patients and Survivors

NCT05805722

RECRUITING NA

Impact of 4PCP on Practitioner and Patient Outcomes

NCT05580419

RECRUITING NA

Periaqueductal Gray-vagus Nerve Interface Malfunction Explain the Natural History With Its Numerous Co-morbidities?

NCT05618054

RECRUITING Phase 2

Vitamin D Supplementation on Reported Rates of Taxane-Induced Neuropathy

NCT05259527

RECRUITING Phase 1

Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease

NCT05548452

RECRUITING

DMCRN-02-001: Assessing Pediatric Endpoints in DM1

NCT05224778

RECRUITING Phase 1

Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan

NCT05194111

RECRUITING NA

Transspinal Stimulation With and Without Blood Flow Restricted Exercise Via Telehealth in Persons With Tetraplegia

NCT05423600

RECRUITING Phase 2

Interleukin-1 Blockade in Acute Myocardial Infarction to Prevent Heart Failure

NCT05177822

RECRUITING NA

Preventing Firearm Violence in Youth: A Hospital-based Prevention Strategy

NCT05078164

RECRUITING NA

Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 3

NCT04916340

RECRUITING

Cardiovascular Health & Early Stress

NCT06557707

RECRUITING NA

Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 2

NCT04922762

RECRUITING NA

Mindful Moms Randomized Control Trial

NCT04886856

RECRUITING NA

Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 1

NCT04916327

RECRUITING NA

Preventing Retaliatory Gun Violence in Violently Injured Adults

NCT04813185

RECRUITING

CIMR Neuromuscular Research Biobank

NCT05434572

RECRUITING NA

Improving Communication and Adherence in Black Breast Cancer Survivors (Sisters Informing Sisters)

NCT05334732

RECRUITING Phase 2

Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer

NCT04643366

RECRUITING Phase 1

Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

NCT03919292

RECRUITING

Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)

NCT03981575

ACTIVE NOT RECRUITING Phase 3

De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients

NCT06001320

ACTIVE NOT RECRUITING NA

Improving Transition Care for Adolescents and Young Adults With Type 1 Diabetes

NCT05639088

ACTIVE NOT RECRUITING

Defining Endpoints in Becker Muscular Dystrophy

NCT05257473

ACTIVE NOT RECRUITING Phase 1

Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer

NCT04502602

ACTIVE NOT RECRUITING Phase 2

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

NCT02957968

ACTIVE NOT RECRUITING NA

Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer

NCT02515110

NOT YET RECRUITING NA

A Prospective Evaluation of Clinical Outcomes in Acute Ischemic Stroke After Endovascular Treatment w/Doppler

NCT07013396

NOT YET RECRUITING Phase 2

Single FrAction Interstitial BreaSt BracHytherApy

NCT07654257

NOT YET RECRUITING Phase 2

Sacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior Chemotherapy

NCT07639086

NOT YET RECRUITING NA

TENS of Auricular Vagal Nerve for Radiation Necrosis

NCT07680127

NOT YET RECRUITING NA

Young Adult-Mediated Intervention to Increase Colorectal Cancer Screening

NCT05936931

NOT YET RECRUITING Phase 1

Safety and Tolerability Study of VVZ-2471 in Healthy Volunteers

NCT07531316

NOT YET RECRUITING Phase 1

Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma

NCT07365839

NOT YET RECRUITING NA

Virtual Housecalls: Redesigning Pediatric Primary Care Adolescent Obesity Treatment

NCT07246603

NOT YET RECRUITING NA

Enhancing Addiction Treatment Through Psychoeducation

NCT07178158

NOT YET RECRUITING NA

Using Apollo Neuro in Autistic Children With Self-Injurious Behavior

NCT07648420

NOT YET RECRUITING NA

The Impact of Improved Vagal Function on Periaqueductal Gray Connectivity

NCT05618067

NOT YET RECRUITING

Southeastern ATTR Amyloidosis Consortium: SEATTRAC Family Registry

NCT05974644

NOT YET RECRUITING NA

Enhancing an Existing Prevention Strategy to Reduce Intentional Firearm Injuries Among High-risk Youth (Phase 1)

NCT07305467

COMPLETED NA

Sleep Extension to Improve Sleep Efficiency and QoL in HF With Preserved Ejection Fraction: the SLEEP-HF Pilot Study

NCT06567925

COMPLETED Phase 2

CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial

NCT06439420

COMPLETED NA

Resin Polymer (NuSmile BioFlx) Compared to Stainless Steel Crowns (3M ESPE) for Restoration of Primary Molar Teeth

NCT06354634

COMPLETED NA

Zirconia-based Primary Anterior Crowns With Retention Grooves Versus Without Retention Grooves

NCT06354647

← Previous Page 2 of 12 Next →

Phase Distribution

PhaseTrial count
Phase 1 80
Phase 2 65
Phase 3 13
Phase 4 22

What is open in the Virginia Commonwealth University pipeline

77 recruiting of 558 indexed (14% open); 380 completed (68%).

Phase mix: 35 late (III/IV) vs 145 early (I/II) (early-phase heavy).

Top condition: Obesity (8 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Virginia Commonwealth University: open-pipeline peers nationwide

Peers matched on 558 registered trials and 14% open enrollment, not the therapeutic-area sidebar.

Virginia Commonwealth University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600 5%10%15%20%25% Total trials Recruiting share Virginia Commonwealth UniversityAmgenMerck Sharp & DohmeUniversity of Maryland, BaltimoreOhio State UniversityLindenwood UniversityBeiGeneReproductive Medicine Associates of New JerseyUniversity of Cincinnati
Virginia Commonwealth University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Virginia Commonwealth University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 558 trials (± recruiting share)

Sponsors near 14% open enrollment (± trial volume)

What to do with this Virginia Commonwealth University page

558 registered trials is a research-attention snapshot, not an endorsement of Virginia Commonwealth University or any single study.

  • 77 of Virginia Commonwealth University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition Virginia Commonwealth University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Virginia Commonwealth University pipeline card: 558 registered trials from official public datasets.Report a data error.